A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis

Trial Profile

A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs GSK 835726 (Primary) ; Cetirizine
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2012 Planned number of patients added (54) as reported by European Clinical Trials Database record.
    • 26 May 2012 Company UCB added to associations field as reported by European Clinical Trials Database record.
    • 26 May 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top